drugset / Trial / NCT02583269

Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery

NCT02583269 ↗

Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I trial studies the side effects and the best dose of muscadine grape skin extract (MGE) in treating patients with malignancy (tumor or cancer) that has spread to other parts of the body or cannot be removed by surgery. MGE is a nutritional supplement containing an extract of the skin of muscadine grape that has shown anti-cancer activity in laboratory studies and may be able to fight or kill malignant cells.

Timeline

Start
2016-03
Primary completion
2017-12-19
Completion
2023-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Muscadine Grape Skin Extract Unknown 320 mg Oral
Subject Muscadine Grape Skin Extract Unknown 1600 mg Oral